Microbot Medical Secures Grant for Robotic System Development

Microbot Medical ( (MBOT) ) has provided an announcement.

Between July 29 and August 1, 2025, Microbot Medical Inc. issued 4,344,286 shares of its common stock through the exercise of Series G preferred investment options, raising approximately $7.6 million. On August 5, 2025, the company announced it received a non-dilutive grant of NIS 2.15 million from the Israel Innovation Authority to enhance its operational capabilities, particularly in preparation for the commercialization of its LIBERTY® Endovascular Robotic System, pending FDA marketing clearance. This grant underscores the company’s market potential and competitive advantages, strengthening its financial position and operational readiness.

The most recent analyst rating on (MBOT) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Microbot Medical stock, see the MBOT Stock Forecast page.

More about Microbot Medical

Microbot Medical Inc. is a pre-commercial stage medical technology company focused on redefining endovascular robotics. It has developed the world’s first single-use, fully disposable endovascular robotic system, aiming to improve the quality of care for patients and providers globally.

Average Trading Volume: 1,734,714

Technical Sentiment Signal: Buy

Current Market Cap: $92.76M

For detailed information about MBOT stock, go to TipRanks’ Stock Analysis page.